Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MenC-TT · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| MenC-TT | BIOLOGICAL | - |
| Hib-MenC-TT | BIOLOGICAL | - |
Inclusion Criteria: * Healthy toddlers (12-15 m) with at least 1 dose of the 3-dose vaccination course of MenC or Hib-MenC vaccine in study 711202/001, OR without previous vaccination against MenC disease but with completed primary vaccination according to the German Standing Committee on Immunizat...
MenC-TT is an investigational vaccine being studied for the prevention of meningococcal infections, specifically infections caused by Neisseria meningitidis serogroup C. It is being evaluated in infants and toddlers as part of GSK's meningococcal vaccine development program.
MenC-TT is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The vaccine is part of GSK's infectious disease portfolio and is currently in clinical development.
MenC-TT is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. Two Phase 2 studies have been completed, and the vaccine is not currently in active clinical trials.
MenC-TT has been studied in two completed Phase 2 trials. NCT00135486 evaluated the vaccine in infants starting at 8 weeks of age, and NCT00135564 evaluated it in toddlers starting at 12 months of age. Both trials enrolled healthy participants and focused on meningococcal infections.
MenC-TT is a conjugate vaccine that links the capsular polysaccharide of Neisseria meningitidis serogroup C to a tetanus toxoid carrier protein. This design is intended to elicit a T-cell-dependent immune response, producing protective antibodies against serogroup C meningococcal disease.